LUCIANA DOS SANTOS HENRIQUES
Índice h a partir de 2011
3
Projetos de Pesquisa
Unidades Organizacionais
Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina - Médico
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
conferenceObject Rituximab - Efficacy and adverse events in selected children and adolescents with challenging idiopathic nephrotic syndrome (INS)(2016) PADOVAN, F. L.; SOUZA, K. M.; LANDENBERGER, C. F. S.; HENRIQUES, L. S.; SCHVARTSMAN, B. G. S.; VAISBICH, M. H.- Pharmacokinetics of cyclosporin - a microemulsion in children with idiopathic nephrotic syndrome(2012) HENRIQUES, Luciana dos Santos; MATOS, Fabiola de Marcos; VAISBICH, Maria HelenaOBJECTIVE: We present a prospective study of a microemulsion of cyclosporin to treat idiopathic nephrotic syndrome in ten children with normal renal function who presented cyclosporin trough levels between 50 and 150 ng/ml and achieved complete remission with cyclosporin. To compare the pharmacokinetic parameters of cyclosporin in idiopathic nephrotic syndrome during remission and relapse of the nephrotic state. METHOD: The pharmacokinetic profile of cyclosporin was evaluated with the 12-hour area under the time-concentration curve (auc0-12) using seven time-point samples. This procedure was performed on each patient during remission and relapse with the same cyclosporin dose in mg/kg/day. The 12-hour area under the time-concentration curve was calculated using the trapezoidal rule. All of the pharmacokinetic parameters and the resumed 4-hour area under the time-concentration curve were correlated with the 12-hour area under the time-concentration curve. ClinicalTrials.gov: NCT01616446. RESULTS: There were no significant differences in any parameters of the pharmacokinetic of cyclosporin during remission and relapse, even when the data were normalized by dose. The best correlation with the 12-hour area under the time-concentration curve was the 4-hour area under the time-concentration curve on remission and relapse of the disease, followed by the 2-hour level after cyclosporin (c2) dosing in both disease states. CONCLUSIONS: These data indicate that the same parameters used for cyclosporin therapeutic monitoring estimated during the nephrotic state can also be used during remission. Larger controlled studies are needed to confirm these findings.
bookPart Síndrome nefrótica idiopática em crianças(2014) HENRIQUES, Luciana dos Santos; VAISBICH, Maria Helena- POSTOPERATIVE OUTCOME OF PEDIATRIC PATIENTS UNDERGOING RENAL TRANSPLANTATION(2013) PADOVAN, Fabiola Lucia; COUTO, Saulo Brasil do; PINTO, Gabriela; MENEZES, Aline Motta; SAKITA, Luciana Henrique dos Santos; METRAN, Camila Cardoso; SILVA, Joao Domingos Montoni da; WATANABE, Andreia; VAISBICH, Maria Helena; DELGADO, Arthur Figueiredo; NAHAS, William Carlos; SCHVARTSMAN, Benita Galassi SoaresBJECTIVE: To evaluate the postoperative outcome in the Intensive Care Unit (ICU) in the first month after kidney transplant. PATIENTS AND METHODS: Thirty-two patients (33 transplants), 21 male, age: 9.5 ± 3.1 yrs. Retrospective study from July/2008 to March/2012 through the variables: cold ischemia time, PRISM, mechanical ventilation (MV), vasoactive drugs (VAD), immunosuppression, infection, surgical complications, dialysis, renal function (CrCl), diuresis, hospitalization length and mortality. Statistics: Fischer and Pearson. RESULTS: Causes of CKF: uropathy-19, glomerulopathy-3, tubulopathy-2, other-7. Cold ischemia: 20hs median. PRISM score: 1.3% (0.2–6.2%), FiO2 max: 30% (21–60%), MV: 1d (0–10d), VAD 18/33 1D(0–6d). 10/33 transplants used thymoglobulin, 23/33 basiliximab. Infections: catheter-related-4, urinary-2,peritonitis-2, sepsis-1. Surgical complications: bleeding-4, thrombosis-3, urinary fistula-1. Of 5/32 dialyzed. CrCl and diuresis first postoperative day: 20 mL/min/1.73 m2 and 3.6 mL/kg/h and at 30 days: 90 mL/min/1.73 m2 and 3.7 mL/kg/h. There was an inverse correlation between cold ischemia time and CrCl in the 1st postoperative day (p = 0.01 and r = 0.45), not seen at 30d. Hospitalization length ICU = 4d (2–23d), total 15d (5 – 45d). There was no difference in infection, MV duration, use of VAD, CrCl, ICU and total hospitalization length between thymoglobulin X basiliximab use (p > 0.05). However duration of VAD utilization was higher for Thymoglobulin (p = 0.05). One patient died from sepsis (3%). CONCLUSION: The outcome after renal transplantation was satisfactory, with short ICU stay, but high use of vasoactive drugs. Bleeding was the most common surgical complication. The patient and graft survival after 1 month of transplantation was 97% and 91%, respectively.
- The long-term use of enalapril and hydrochlorothiazide in two novel mutations patients with Dent's disease type 1(2012) VAISBICH, Maria Helena; HENRIQUES, Luciana dos Santos; IGARASHI, Takashi; SEKINE, Takashi; SEKI, George; KOCH, Vera HDent's disease type 1 is an X-linked tubular disease caused by mutations in the renal chloride channel CLCN-5, and it is characterized by low molecular weight proteinuria, hypercalciuria, nephrocalcinosis, and renal failure. Several cases have been described in which the only presenting symptoms were asymptomatic proteinuria, and focal segmental or global glomerulosclerosis. The renal failure in these patients may be caused by hypercalciuria and persistent proteinuria. Therefore, angiotensin converse enzyme inhibitor and thiazides could be useful. Our aim is to report the effects of these drugs in two novel mutations patients with Dent's disease type 1. In this report, no significant correlations between dosage of hydrochlorothiazide and calciuria and no significant correlations between proteinuria and dosage of enalapril were detected. This is important since these are polyuric patients and these drugs could be dangerous to their renal function.
- Síndrome nefrótica como a primeira manifestação da esclerodermia sistêmica juvenil(2017) COUTO, Saulo B.; SALLUM, Adriana M.; HENRIQUES, Luciana S.; MALHEIROS, Denise M.; SILVA, Clovis A.; VAISBICH, Maria H.
- Uso do eculizumab na síndrome hemolítica urêmica atípica: relato de caso e revisão da literatura(2013) VAISBICH, Maria Helena; HENRIQUES, Luciana dos Santos; WATANABE, Andréia; PEREIRA, Lilian Monteiro; METRAN, Camila Cardoso; MALHEIROS, Denise Avancini; MODANEZ, Flávia; SILVA, João Domingos Montoni da; VIEIRA, Simone; MACEDO, Ana Catarina Lunz; MASSAROPE, Bianca; FURUSAWA, Érika Arai; SCHVARTSMAN, Benita Galassi SoaresSHU atypical (aHUS), that is, not associated with Escherichia coli Shiga toxinproducing, is seen in 5 to 10% of cases of Hemolytic Uremic Syndrome (HUS), and can occur at any age and may be sporadic or familial. The prognosis in these cases is reserved, with high mortality and morbidity in the acute phase of the disease, and about 50% of cases can develop chronic kidney disease. The increased knowledge of the pathogenesis of aHUS (overactivation of the alternative pathway of complement), was accompanied by the appearance of a drug, eculizumab, which acts as an inhibitor of membrane attack complex. Our goal is to report a case of infant with aHUS with excellent clinical and laboratory response with the use of eculizumab. 14 month old infant, previously healthy, male, presented anemia and thrombocytopenia at 12 months of age. He was treated with corticosteroids and forwarded to our service for high blood pressure. However, the scans showed nephrotic proteinuria with renal involvement and hypoalbuminemia with direct Coombs negative. He developed anemia, thrombocytopenia, worsening of renal function and hypertension. Renal biopsy showed thrombotic microangiopathy (TMA). On the non-hemolytic anemia, thrombocytopenia and acute renal failure with histological substrate MAT, was diagnosed of aHUS. The patient received eculizumab excellent clinical and laboratory response. This case shows the importance of early diagnosis and treatment of the aHUS. Eculizumab is effective and keeps long-term remission, avoiding invasive measures such as plasmapheresis, which resolves only part of the picture.
conferenceObject BK virus nephropathy management in pediatric renal transplant recipients: a series of cases(2016) CARDOSO, R.; WATANABE, A.; METRAN, C.; HENRIQUES, L.; DAVID, D.